相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Poly(ADP-ribose) polymerase inhibition in pancreatic cancer
Hans Martin Singh et al.
GENES CHROMOSOMES & CANCER (2021)
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
Pierre-Marie Morice et al.
LANCET HAEMATOLOGY (2021)
Changing the History of Prostate Cancer with New Targeted Therapies
Susana Hernando Polo et al.
BIOMEDICINES (2021)
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Praveen Vikas et al.
FRONTIERS IN ONCOLOGY (2020)
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
Nur Aininie Yusoh et al.
CHEMMEDCHEM (2020)
Recent advancements in PARP inhibitors-based targeted cancer therapy
Ping Zhou et al.
PRECISION CLINICAL MEDICINE (2020)
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
Ethan S. Sokol et al.
JCO PRECISION ONCOLOGY (2020)
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilie et al.
CLINICAL CANCER RESEARCH (2019)
Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.
Junning Cao et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Exploring and comparing adverse events between PARP inhibitors
Christopher J. LaFargue et al.
LANCET ONCOLOGY (2019)
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2019)
Combining PARP Inhibition, Radiation, and Immunotherapy: A Possible Strategy to Improve the Treatment of Cancer?
Mathieu Cesaire et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials
Jian xin Zhou et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Cancers Associated With BRCA1 and BRCA2 Mutations Other Than Breast and Ovarian
Jacqueline Mersch et al.
CANCER (2015)
The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
Helen Cavanagh et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2015)
Associations between BRCA Mutations in High-Risk Breast Cancer Patients and Familial Cancers Other than Breast or Ovary
Jae Myoung Noh et al.
JOURNAL OF BREAST CANCER (2012)
Genetic Interactions in Cancer Progression and Treatment
Alan Ashworth et al.
CELL (2011)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
Exploiting synthetic lethal interactions for targeted cancer therapy
H. Christian Reinhardt et al.
CELL CYCLE (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Dose Escalation Methods in Phase I Cancer Clinical Trials
Christophe Le Tourneau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
分享论文
